EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case Series

Livija Šimičević, Ana Marija Slišković, Majda Vrkić Kirhmajer, Lana Ganoci, Hrvoje Holik, Jozefina Palić, Jure Samardžić, Tamara Božina

Pharmacy · 05.02.2023 · 11 (1) · 29

DOI: 10.3390/pharmacy11010029 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pharmacy, online erschienen am 05.02.2023. Verfasst von Livija Šimičević und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, 10000 Zagreb, Cr…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Croatian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-vitamin K antagonist oral anticoagulants’ interindividual trough concentration variability affects efficacy and safety, especially in bleeding events. Rivaroxaban is metabolised via CYP3A4/5-, CYP2J2-, and CYP-independent mechanisms and is a substrate of two transporter proteins: ABCB1 (MDR1, P-glycoprotein) and ABCG2 (BCRP; breast-cancer-resistance protein). The polymorphisms of these genes may possibly affect the pharmacokinetics of rivaroxaban and, consequently, its safety profile. Rivaroxaban variability may be associated with age, liver and kidney function, concomitant illness and therapy, and pharmacogenetic predisposition. This case series is the first, to our knowledge, that presents multiple risk factors for rivaroxaban-related bleeding (RRB) including age, renal function, concomitant diseases, concomitant treatment, and pharmacogenetic data. It presents patients with RRB, along with their complete clinical and pharmacogenetic data, as well as an evaluation of possible risk factors for RRB. Thirteen patients were carriers of ABCB1, ABCG2, CYP2J2, and/or CYP3A4/5 gene polymorphisms. Possible drug–drug interactions with increased bleeding risk were identified in nine patients. Six patients had eGFR

Schlagwörter

Stichwörter der Autor:innen

drug safetyinteractionsmultidisciplinarypharmacogeneticrisk factorsrivaroxabanrivaroxaban-related bleeding

Autor:innen und Institutionen

  • Division of Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
  • Department of Cardiovascular Diseases, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
  • Department of Internal Medicine, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
  • Department of Internal Medicine, General Hospital Dr Josip Benčević, 35000 Slavonski Brod, Croatia.
  • Department of Medical Chemistry, Biochemistry and Clinical Chemistry, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.

Förderung

  • Croatian Science Foundation

Zitieren

APA

Šimičević, L., Slišković, A. M., Kirhmajer, M. V., Ganoci, L., Holik, H., Palić, J., Samardžić, J., & Božina, T. (2023). Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case Series. Pharmacy, 11(1), 29. https://doi.org/10.3390/pharmacy11010029

Vancouver

Šimičević L, Slišković AM, Kirhmajer MV, Ganoci L, Holik H, Palić J, et al. Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case Series. Pharmacy. 2023;11(1):29. doi:10.3390/pharmacy11010029

BibTeX
@article{imievi2023,
  author = {Šimičević, Livija and Slišković, Ana Marija and Kirhmajer, Majda Vrkić and Ganoci, Lana and Holik, Hrvoje and Palić, Jozefina and Samardžić, Jure and Božina, Tamara},
  title = {Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case Series},
  journal = {Pharmacy},
  year = {2023},
  volume = {11},
  number = {1},
  pages = {29},
  doi = {10.3390/pharmacy11010029}
}
Kostenlos starten →